|
|
Post by saxcmann on Oct 3, 2017 13:07:36 GMT -5
The last notice I received a few weeks back was a loan rate of 50%. loan rate? to borrow is 86% and to loan out via fidelity is 50%. |
|
|
|
Post by saxcmann on Oct 2, 2017 10:30:18 GMT -5
peppy, you're right! the day isn't over. I still feel dilution is near but for now pps is green!
|
|
|
|
Post by saxcmann on Oct 2, 2017 8:52:45 GMT -5
we'll close in red my guess. shorts will pounce unfortunately. I said buy the rumor and sell the news a few times I heard you. |
|
|
|
Post by saxcmann on Oct 2, 2017 8:51:48 GMT -5
today is over. long term it's not over. we freed up 22 million shares so we can dilute. today is over! |
|
|
|
Post by saxcmann on Oct 2, 2017 8:41:24 GMT -5
Well, I was wrong again. News today not enough to shake the shorts. Darn. we'll close in red my guess. shorts will pounce unfortunately. |
|
|
|
Post by saxcmann on Sept 30, 2017 0:55:34 GMT -5
Let's see what FDA says first! My bet would be Mike already knows what the FDA has said. Otherwise, he most likely would not be tweeting what he tweeted! My next bet is that he shares it with us before the market open on Monday! Maybe I am wrong, because after owning this stock for as long as I have, I have certainly expected things that never materialized. But I would bet the farm that good news...no...very good news is finally on its way! I personally have never said this before, and got tired of hearing others say it, but I honestly feel that it is finally true so here goes... Shorts are scared! Have a great weekend Longs!!! I think you're right! ... this time! |
|
|
|
Post by saxcmann on Sept 26, 2017 12:29:23 GMT -5
Keep your fingers crossed, everyone, on that label change - there's a lot of hopes hanging on that. Any downturn in the stock this week will not signal a darn thing - all that remember the couple of days before the AdCom should know that. I remember just before news broke before. you remember that? What was that?? big drop before jump up... |
|
|
|
Post by saxcmann on Sept 25, 2017 12:49:32 GMT -5
Per Mike C
PDUFA date is this Friday. Nothing they are aware of would change this
*he mentioned again toward the end of the presentation. By Friday or possibly over the weekend. in this order.
Big question is how much time between label and recapitalization? could be quick like a day or two? |
|
|
|
Post by saxcmann on Sept 25, 2017 12:43:24 GMT -5
Correct - the transfer of the TASE shares to Nasdaq isn't dilutive. The number of issued and outstanding shares won't change, but Mannkind doesn't get any money either. If they go the convertible route with the 10 million preferred shares (and imo they will), Mannkind will have to increase the number of authorized shares to raise any significant dollars. They could come to an agreement with a buyer, announce the proposed terms and then setup a shareholder vote to approve increase in outstanding shares. If approved, they could then issue the preferred shares and collect the proceeds. It would be dilutive for all existing share holders, but there wouldn't be a flood of new common shares hitting the market to help the shorts cover their positions. Thanks. My question is now answered. Problem for MNKD is cash will be running out probably before this process can be approved by shareholders. Unless it can be expedited. 21 day process,they have time. |
|
|
|
Post by saxcmann on Sept 21, 2017 19:58:20 GMT -5
• Afrezza reaches peak serum insulin concentration in 12 to 15 minutes. • Afrezza tightly regulates postprandial plasma glucose (PPG) via mimicking endogenous prandial insulin secrection (first phase insulin secrection and so on). • Afrezza significantly lowers fasting plasma glucose (FPG), and is accociated with significantly less hypoglycemia and weight gain compared to insulin aspart via the FDA approved Phase 3 clinical trial—Trial 171. How naive was I back in 2012 to believe that being able to take insulin without needles was enough to sell it? We live and learn. about the same time I felt the same way! what was I thinking!? seemed like a no brainer back then. still no sales really...we need label changes I guess. argh! 😠 |
|
|
|
Post by saxcmann on Sept 21, 2017 19:27:42 GMT -5
I don't see ultra making much difference without new trials. The evidence that is out there says Afrezza performs equal to or slightly worse than the existing options and that is the excuse insurers will stick to - Afrezza does not produce better outcomes and they can keep their juicy deals with Novo Nordisk, Sanofi, and Eli Lilly. Now the reduced hypos line has potential, that's a tangible benefit... Though for what it is worth, management has indicated that it would make a difference because PBMs/insurers apparently have deals with subq prandial manufacturers which would become less of a problem if Afrezza is classified as "ultra-rapid". I do wonder if this is simply managements presumption or whether they have clearly been told this by PBMs/insurers. I tend to give some benefit of the doubt to Mike... but at end of the day "show me the money". One way or the other we need better placement on 2018 formularies. I would agree that an adjective on the label isn't going to mean a lot to doctors who can already see the pk/pd profile. Like I said...Ultra is good but reduced hypos is better as far as docs prescribing it. Not sure about formularies regarding better insurance coverage, but sounds like that would be true. |
|
|
|
Post by saxcmann on Sept 18, 2017 13:02:54 GMT -5
I talked to a ( part time MNKD Rep) Not the ones we have now. This was way over a year ago. The stuff that the area SNY rep told her was pure BS. They had no idea how to help patients dose. ( meaning the SNY reps ) That was then...now talking to people out in the field its insurance. People do get their scripts and THEN find out they have to write a letter:-( And if they don't say what the insurance company wants to hear they get rejected. Just ask Hillard. Or the many people that we all know that have been or are still going through it. It didn't work for some because a unit is not a unit. And there were no directions! Kids can figure it out, they don't have as much fear, and are used to technology. We need the dosing to be right on the label. Then we need the different class for better insurance IMO. Exactly Sports! |
|
|
|
Post by saxcmann on Sept 14, 2017 14:17:43 GMT -5
I'm guessing we'll go above 50% next few days. if scripts are good Friday they'll need to hold us down. if label is good then we might see 60% until dilution news hits? Looking at your post history.. do you have a doc friend? If you do how is he doing on Afrezza RX? My doc friend is one of the top prescribers in the United States. For him he has been prescribing afrezza from the start so not much change. I think he's been passing the good word to other endos and primary care docs tho! Change will take time but it's happening... |
|
|
|
Loan Rate
Sept 14, 2017 12:38:38 GMT -5
via mobile
Post by saxcmann on Sept 14, 2017 12:38:38 GMT -5
This thread is way off topic. Fidelity increased the interest they pay for loaned shares to 49% this morning. I'm guessing we'll go above 50% next few days. if scripts are good Friday they'll need to hold us down. if label is good then we might see 60% until dilution news hits? |
|
|
|
Post by saxcmann on Sept 13, 2017 16:47:42 GMT -5
So is 113% common? Doesnt this say you would be insane to try to short this stock right now? No, it says just the opposite. Shorts are willing to pay a big premium to short it. Normally, this shows that the shorts are very confident. I agree they must be very confident to pay those prices! Very confident dilution is coming is the bet? They should be right unless Mike pulls rabbit with partner giving at least $50 million upfront after positive fda label announcement. |
|
